CLASS II ONGOING Drug recall · Reported 26 Jul 2023 · FDA Enforcement Report

Tizanidine Tablets USP, 4 mg recalled by Dr Reddy's Laboratories

Dr Reddy's Laboratories is recalling Tizanidine Tablets USP, 4 mg, distributed nationwide in the US. The recall was initiated on 21 Jun 2023 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot: T2100585, T2100586, T2100587, Exp 12/2023
NDC55111-179, 55111-180
UPC0355111180104, 0355111179108
Quantity recalled17,548 1000-countbottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0923-2023
FDA event ID
92564
Recalling firm
Dr Reddy's Laboratories, Ranasthalam Mandal, Srikakulam, N/A
Manufacturer
Dr. Reddy's Laboratories Limited
Classification
Class II
Status
Ongoing
Recall initiated
21 Jun 2023
FDA classified
17 Jul 2023
Reported
26 Jul 2023
Type
N/A
Customers notified by
N/A
Reason category
Potency & Assay

Timeline

21 Jun 2023Recall initiated by company
17 Jul 2023Classified by FDA+26 days
26 Jul 2023Published in enforcement report+9 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed dissolution specification: Out of specification results observed in 24-month long term stability testing.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Tizanidine Tablets USP, 4 mg, 1000-Count bottle, Rx Only, Manufactured by Dr. Reddy's Laboratories Limited Srikakulam - 532 409 India. NDC 55111-180-10

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Tizanidine Tablets USP, 4 mg recalled?

Yes. Dr Reddy's Laboratories recalled Tizanidine Tablets USP, 4 mg on 21 Jun 2023. The recall is Class II and its status is Ongoing. Recall number D-0923-2023.

Why was it recalled?

Failed dissolution specification: Out of specification results observed in 24-month long term stability testing.

Which lots are affected?

Lot: T2100585, T2100586, T2100587, Exp 12/2023

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Dr Reddy's Laboratories

All 165

Other Tizanidine recalls

All 11